Deprescribing Anticholinergic and Sedative Drugs to Reduce Polypharmacy in Frail Older Adults Living in the Community: A Randomized Controlled Trial. Jamieson H, et al, J Gerontol A Biol Sci Med Sci 2023.
Notes sur les tags :
Réaliser des modifications :
Pour modifier ce document, il est nécessaire d'être connecté au site. Pour cela, assurez-vous d'avoir des identifiants valides. Si vous n'en avez pas,
contactez-nous. Pour vous connecter, cliquez sur l'icône
dans la barre de navigation.
Résumé et points clés
Background: Polypharmacy is associated with poor outcomes in older adults. Targeted deprescribing of anticholinergic and sedative medications may improve health outcomes for frail older adults. Our pharmacist-led deprescribing intervention was a pragmatic 2-arm randomized controlled trial stratified by frailty. We compared usual care (control) with the intervention of pharmacists providing deprescribing recommendations to general practitioners.
Methods: Community-based older adults (≥65 years) from 2 New Zealand district health boards were recruited following a standardized interRAI needs assessment. The Drug Burden Index (DBI) was used to quantify the use of sedative and anticholinergic medications for each participant. The trial was stratified into low, medium, and high-frailty. We hypothesized that the intervention would increase the proportion of participants with a reduction in DBI ≥ 0.5 within 6 months.
Results: Of 363 participants, 21 (12.7%) in the control group and 21 (12.2%) in the intervention group had a reduction in DBI ≥ 0.5. The difference in the proportion of -0.4% (95% confidence interval [CI]: -7.9% to 7.0%) provided no evidence of efficacy for the intervention. Similarly, there was no evidence to suggest the effectiveness of this intervention for participants of any frailty level.
Conclusion: Our pharmacist-led medication review of frail older participants did not reduce the anticholinergic/sedative load within 6 months. Coronavirus disease 2019 (COVID-19) lockdown measures required modification of the intervention. Subgroup analyses pre- and post-lockdown showed no impact on outcomes. Reviewing this and other deprescribing trials through the lens of implementation science may aid an understanding of the contextual determinants preventing or enabling successful deprescribing implementation strategies.
Références de l'article
- Deprescribing Anticholinergic and Sedative Drugs to Reduce Polypharmacy in Frail Older Adults Living in the Community: A Randomized Controlled Trial.
- Deprescribing Anticholinergic and Sedative Drugs to Reduce Polypharmacy in Frail Older Adults Living in the Community: A Randomized Controlled Trial.
- Jamieson H, Nishtala PS, Bergler HU, Weaver SK, Pickering JW, Ailabouni NJ, Abey-Nesbit R, Gullery C, Deely J, Gee SB, Hilmer SN, Mangin D
- The journals of gerontology. Series A, Biological sciences and medical sciences
- 2023
- J Gerontol A Biol Sci Med Sci. 2023 Aug 27;78(9):1692-1700. doi: 10.1093/gerona/glac249.
- Humans, Aged, Polypharmacy, Frail Elderly, *Deprescriptions, Cholinergic Antagonists/adverse effects, *Frailty/drug therapy, *COVID-19, Communicable Disease Control, Hypnotics and Sedatives/therapeutic use
- Fragilité, COVID19
- Liens
- Traduction automatique en Français sur Google Translate
- DOI: 10.1093/gerona/glac249
- PMID: 36692224
- Articles similaires
- Cité par
- Références
- Texte complet gratuit
- Twitter
- Twitter cet article (lien vers l'article)
- Twitter cet article (lien vers cette page)
Éditer la discussion
Références